The Australian share market has finished its worst week since October 2008 with a modest daily gain.…
At a time when the world is readying to take the necessary precautions to fight the spread of Covid-19 pandemic, the Directorate General of Shipping has come out with rules to ensure that trade goes on amid the coronavirus scare.
Shipping services are required to continue to be operational so that vital goods and essential commodities like fuel, medical supplies, food grains etc, are delivered and to ensure that the economic activity of the nation is not disrupted.
According to the DG Shipping order to all stakeholders, which include major as well minor ports, the master of a vessel, before arrival at its first port of call in India, shall ascertain the state of health of each person on board on the vessel and submit a declaration to the health authorities of the port.
If the maritime declaration of health given by the master is found to be incorrect and not reflecting the factual conditions of health of persons on board the vessel, the master is liable to be prosecuted in line with applicable laws.
All the agents of the vessel therefore shall ensure that information regarding
Pharmacyclics Inc, a Silicon Valley-based biopharmaceutical company and part of AbbVie, which itself is a spin-off from pharmaceutical giant Abbott, has lost a patent for its anti-cancer drug ibrutinib in India, following a post-grant objection raised by Andhra Pradesh-based Laurus Labs.
The Patent Office had, earlier this month revoked the patent observing that the claims made by Pharmacyclics are obvious to an ordinary person skilled in the art and that the drug lacks any inventive step that would make it superior to other existing formulations.
According to Pharmacyclics, ibrutinib is a small molecule that works by inhibiting an enzyme called protein kinase, which controls the rate at which certain cells multiply. It claims that the drug works differently from existing chemotherapy and immunotherapy solutions, and is sold in the US under the brand name Imbruvica. It is a once-daily, first-in-class Bruton’s tyrosine kinase (BTK) inhibitor administered orally, and has been jointly developed and commercialised by Pharmacyclics and Janssen Biotech, Inc.
Pharmacyclics filed a patent application of this inhibitors in 2009 and obtained a patent on September 25, 2014. Laurus filed a post-grant challenge on September 24, 2015 on several
As responsible citizens of this country, it is our duty to pay taxes on time. But what we need to determine in this regard is how much we have to pay and where we can avail tax deductions.
Moreover, we need to keep an eye on tax rates and changes in tax forms which vary year to year. While the first-timers may find the whole thing to be a little hectic, calculation of taxable income is easy when you know where to start and what to consider while you are calculating tax returns for a financial year.
In this article, we sum up everything that you need to know for calculating Income Tax for 2018-2019.
Where to start?
Basically, one has to calculate income tax on the basis of his/her salary. There are a few income slabs and the rate of tax depends on the particular slab that your annual income falls into. Therefore, you need to calculate your total taxable income by applying the tax rate on your salary. The taxpayer needs to apply deductions such as LTA exemptions, HRA, investments, interest on home loan etc. on the total taxable income to find out the net taxable income